Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 15;10(6):1208.
doi: 10.3390/jcm10061208.

Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot

Matevž Kastrin  1 , Vilma Urbančič Rovan  2   3 , Igor Frangež  1   3
Affiliations

Possible Advantages of S53P4 Bioactive Glass in the Treatment of Septic Osteoarthritis of the First Metatarsophalangeal Joint in the Diabetic Foot

Matevž Kastrin et al. J Clin Med. .

Abstract

Biomechanically, the great toe with its metatarsophalangeal (MTP) joint plays a key role in standing and walking, making the first MTP joint one of the main predilection sites for ulcer formation, and consequently for bone and joint infection and even amputation. If conservative treatment fails, the main goal of surgery is to remove all infected tissue and preserve the first ray. To improve surgical outcomes, development of new biomaterials like Bioactive Glass S53P4 has begun. Bioactive Glass is useful because of its antibacterial properties; furthermore, its osteostimulative and osteoconductive qualities make the bone substitute particularly suitable as a bone defect filler for the treatment of osteomyelitis. The aim of our retrospective observational study was to compare the outcomes following ulcerectomy with segmental resection of the infected joint and bone and temporary stabilization with an external fixator, both with and without added Bioactive Glass. A comparison of added Bioactive Glass with the traditional surgical treatment in septic osteoarthritis of the first MTP joint showed Bioactive Glass to be effective. During a one-year follow-up, patients with Bioactive Glass required no additional antibiotic therapy or surgical intervention. Bioactive Glass, when applied to the diabetic foot, showed itself to be a safe bone substitute biomaterial.

Keywords: bioactive glass; diabetic foot; diabetic foot osteomyelitis; foot ulcer; segmental resection of the first MTP joint; septic osteoarthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Segmental resection of the first MTP joint with Bioactive Glass S53P4; MTP: metatarsophalangeal.
Figure 2
Figure 2
Segmental resection of the first MTP joint with a Septopal® Chain.
See this image and copyright information in PMC

References

    1. Fernando M.E., Crowther R.G., Cunningham M., Lazzarini P.A., Sangla K.S., Golledge J. Lower limb biomechanical characteristics of patients with neuropathic diabetic foot ulcers: The diabetes foot ulcer study protocol. BMC Endocr. Disord. 2015;15:1–11. doi: 10.1186/s12902-015-0057-7. - DOI - PMC - PubMed
    1. Dalla Paola L., Carone A., Morisi C., Cardillo S., Pattavina M. Conservative Surgical Treatment of Infected Ulceration of the First Metatarsophalangeal Joint With Osteomyelitis in Diabetic Patients. J. Foot Ankle Surg. 2015;54:536–540. doi: 10.1053/j.jfas.2014.08.004. - DOI - PubMed
    1. Quebedeaux T.L., Lavery L.A., Lavery D.C. The development of foot deformities and ulcers after great toe amputation in diabetes. Diabetes Care. 1996;19:165–167. doi: 10.2337/diacare.19.2.165. - DOI - PubMed
    1. Lavery L.A., Lavery D.C., Quebedeax-Farnham T.L. Increased foot pressures after great toe amputation in diabetes. Diabetes Care. 1995;18:1460–1462. doi: 10.2337/diacare.18.11.1460. - DOI - PubMed
    1. Murdoch D.P., Armstrong D.G., Dacus J.B., Laughlin T.J., Morgan C.B., Lavery L.A. The natural history of great toe amputations. J. Foot Ankle Surg. 1997;36:204–208. doi: 10.1016/S1067-2516(97)80116-0. - DOI - PubMed

LinkOut - more resources